RadNet: AI Study and GE HealthCare Partnership as New Drivers
Breast cancer records 2.3 million new diagnoses and 700,000 deaths each year.
The addressable market potential is $100 billion.
Reading Time: 1 minute
RadNet (RDNT) is, for me, one of the top breakout candidates as a leading operator of outpatient imaging centers. The recently published ASSURE study shows that, within the framework of the EBCD program for early breast cancer detection, the Breast Suite improves the cancer detection rate by 21.6% compared to conventional 3D mammography thanks to AI. EBCD AI revenues recently rose by 28.7% with nationwide coverage of 45% in RadNet centers. The Digital Health segment serves over 2,000 customers worldwide with AI cancer detection (Deep Health) as...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
